Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 232.80K | 251.50K | 244.20K | 477.40K | 245.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 256.60K | 277.00K | 324.60K | 729.70K | 368.50K |
| Operating Income | -256.60K | -277.00K | -324.60K | -729.70K | -368.50K |
| Income Before Tax | -277.00K | -307.70K | 1.06M | -747.20K | -382.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -277.00K | -307.70K | 1.06M | -747.20K | -382.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -277.00K | -307.70K | 1.06M | -747.20K | -382.00K |
| EBIT | -256.60K | -277.00K | -324.60K | -729.70K | -368.50K |
| EBITDA | -252.60K | -273.10K | -320.10K | -724.00K | -363.00K |
| EPS Basic | -0.01 | -0.01 | 0.05 | -0.04 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.05 | 0.03 | -0.02 | -0.02 |
| EPS Diluted | -0.01 | -0.01 | 0.04 | -0.04 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.05 | 0.03 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 27.30M | 23.39M | 21.78M | 19.22M | 15.78M |
| Average Diluted Shares Outstanding | 27.30M | 23.39M | 22.28M | 19.22M | 15.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
